Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EBITDA (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed EBITDA for 12 consecutive years, with -$157.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 316.68% to -$157.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$358.5 million through Dec 2025, down 224.82% year-over-year, with the annual reading at -$358.5 million for FY2025, 224.82% down from the prior year.
  • EBITDA hit -$157.7 million in Q4 2025 for Viking Therapeutics, down from -$90.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$12.7 million in Q4 2021 to a low of -$157.7 million in Q4 2025.
  • Historically, EBITDA has averaged -$33.9 million across 5 years, with a median of -$20.3 million in 2023.
  • Biggest five-year swings in EBITDA: increased 6.09% in 2024 and later tumbled 329.01% in 2025.
  • Year by year, EBITDA stood at -$12.7 million in 2021, then tumbled by 48.41% to -$18.9 million in 2022, then decreased by 27.46% to -$24.1 million in 2023, then plummeted by 57.07% to -$37.8 million in 2024, then plummeted by 316.68% to -$157.7 million in 2025.
  • Business Quant data shows EBITDA for VKTX at -$157.7 million in Q4 2025, -$90.2 million in Q3 2025, and -$65.5 million in Q2 2025.